ARCA biopharma, Inc. (ABIO)

2.2500 0.0000 (0.00%) At close: 04:00PM EST

ARCA biopharma, Inc.

10170 Church Ranch Way
Suite 100
Westminster, CO 80021
United States
720 940 2200
http://www.arcabio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 11

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Michael R. Bristow M.D., Ph.D.	Co-Founder, Pres, CEO & Director	441.61k	N/A	1945
Mr. Thomas A. Keuer	Chief Operating Officer	402.61k	N/A	1959
Mr. Christopher D. Ozeroff	Sr. VP, Gen. Counsel & Sec.	376.38k	N/A	1959
Mr. C. Jeffrey Dekker	Chief Financial Officer	N/A	N/A	1965
Dr. Debra Marshall FACC, M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Corporate Governance

ARCA biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.